Rocket Pharmaceuticals, Inc.今日宣布，已与美国食品药品监督管理局（FDA）就完成其在Danon病治疗领域主打候选药物Rp-A501的关键性II期临床试验的路径达成了共识。
这一里程碑式的进展，标志着该公司在针对罕见心脏病——Danon病的基因疗法开发进程中，迈出了具有决定性的坚实一步。据悉，该共识涵盖了临床开发计划中关键的后续步骤及监管层面的期望要求。
通过此次与监管机构的积极且富有建设性的沟通，Rocket Pharmaceuticals有望更清晰地界定并执行其临床策略，从而加速评估Rp-A501的安全性及有效性。Danon病作为一种严重的X连锁遗传性心肌病，长期以来面临治疗手段极其匮乏的困境，患者预后极差。
公司方面表示，获得FDA的明确指引将有助于其高效地推进这一创新疗法的后期临床开发工作，并有潜力尽早为这一急需满足的医疗需求带来变革性的治疗选项。此次公布的利好动态，也进一步巩固了Rocket Pharmaceuticals在罕见病基因治疗领域的领先地位，为其研发管线的持续进展注入了新的动力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.